SNPMiner Trials (Home Page)
Report for Clinical Trial NCT00280215
 Developed by Shray Alag, 2020-2021.
SNP Clinical Trial Gene 
      This study will test the effectiveness of two medications: ACEI (angiotensin converting
      enzyme inhibitor)and ARB (angiotensin receptor blocker) in reducing the renal injury induced
      by hyperoxaluria in patients with Primary Hyperoxaluria.
      Hypothesis: Calcium oxalate crystal deposition in the kidney causes inflammation and
      resulting injury to kidney tissue. Angiotensin blockade will improve these changes, thus
      slowing the progression of renal insufficiency in patients with Primary Hyperoxaluria.
    
  3  Interventions 
 Name: ACEI / Angiotensin converting enzyme inhibitor
Description: Patients will be randomized to a combination of Angiotensin Converting Enzyme Inhibitor and Angiotensin Receptor Blocker, Patients will be randomized to a combination of ARB(losartan 50 mg daily in adult patients, 0.7 mg/kg/day in patients < 40 kg) ACE-I (lisinopril 10 mg daily in adult patients, 0.15 mg/kg/day in pediatric patients < 40 kg) to be taken for 24 months.
 Type: Drug
 Name: ARB /Angiotensin Receptor Blocker
Description: Patients will be randomized to a combination of Angiotensin Converting Enzyme Inhibitor and Angiotensin Receptor Blocker,Patients will be randomized to a combination of ARB(losartan 50 mg daily in adult patients, 0.7 mg/kg/day in patients < 40 kg) ACE-I (lisinopril 10 mg daily in adult patients, 0.15 mg/kg/day in pediatric patients < 40 kg) to be taken for 24 months.
 Type: Drug
 Name: Placebo
Description: Patients will receive placebo for 24 months
 Type: Drug
  
Primary Outcomes 
 Measure: Two-year change in the urinary markers of renal tubular injury and interstitial fibrosis Time: 2 years
   
Secondary Outcomes 
 Measure: Rate of change in 1. Renal tubular injury markers and 2. Renal function as determined by serum creatinine and creatinine clearance. Time: 2 years
 
Purpose: Prevention
Allocation: Randomized
Parallel Assignment 
There is one SNP
SNPs
1 G170R 
Homozygosity for the G170R mutation of AGXT h. --- G170R ---